Mass drug administration with dihydroartemisinin-piperaquine and primaquine to reduce malaria in a moderate-low transmission setting in Senegal

Over the past two decades in Senegal, the scale-up of malaria control measures [e.g., access to prompt testing and case management, LLINs, and SMC] has led to a 78% reduction in malaria incidence. However, gains have not been uniform, with lower transmission areas in the north implementing pre-elimination activities and higher transmission areas in the south implementing control interventions (including SMC). The purpose of this study is determine whether MDA will be able to rapidly reduce malaria incidence in areas of moderate-to-low malaria transmission of southern Senegal (where control activities are ongoing) so that the program can reorient their malaria strategy to implement elimination interventions in these settings.

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 24000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Two-arm cluster randomized controlled trial. A total of 60 villages will be randomized to receive the intervention (three rounds of MDA with DHA-PPQ + SLD-PQ) or control (standard malaria control measures, including SMC) at a ratio of 1:1
Masking: None (Open Label)
Primary Purpose: Prevention

ClinicalTrials.gov - Project details

Drug Resistance
Drug-based Strategies
Financing & Economics
Impact of Interventions
Operational Research

May 2021 — Dec 2022

Senegal